Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Earnings Preview: BioXcel Therapeutics
BioXcel Therapeutics (NASDAQ:BTAI) is set to give its latest quarterly earnings report on Thursday, 2023-03-09. Here’s what investors…
Analyst Reiterates This Alzheimer’s Candidate As Top Idea For 2023
Mizuho raised the price target on BioXcel Therapeutics Inc (NASDAQ:BTAI) from $24 to $38, with a Buy rating. Since the analyst’s previous…
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $85 to $73.
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
Goldman Sachs Upgrades BioXcel Therapeutics to Neutral, Announces $16 Price Target
Goldman Sachs analyst Corinne Jenkins upgrades BioXcel Therapeutics (NASDAQ:BTAI) from Sell to Neutral and announces $16 price target.
Cramer On This Stock Down 65% Year-To-Date: ‘I Do Believe It’s Bottoming, But I Don’t Know What Gets It Higher’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."
Mizuho Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $18
Mizuho analyst Graig Suvannavejh maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $19 to $18.
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Raises Price Target to $76
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $75 to $76.
BioXcel Therapeutics Q3 EPS $(1.49) Misses $(1.35) Estimate, Sales $137.00K Miss $1.09M Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(1.35) by 10.37 percent. This is a 55.21 percent decrease over losses of $(0.96) per share